We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Actavis Elizabeth is suing the FDA for refusing to file the company’s ANDA for a generic version of Shire’s attention deficit hyperactivity disorder treatment Vyvanse because the drug’s new chemical entity (NCE) exclusivity was still in effect.